1 / 41

Conflict of Interest Declaration: Nothing to Disclose

Conflict of Interest Declaration: Nothing to Disclose. Presenter : Sophie Lamoureux Title of Presentation: A Comparison of Stereotactic Body Radiotherapy with Hypofractionated Radiotherapy for Early Stage Non-small Cell Lung Cancer: Control Rates from a Regional Cancer Centre

saxton
Télécharger la présentation

Conflict of Interest Declaration: Nothing to Disclose

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Conflict of Interest Declaration: Nothing to Disclose Presenter: Sophie Lamoureux Title of Presentation: A Comparison of Stereotactic Body Radiotherapy with Hypofractionated Radiotherapy for Early Stage Non-small Cell Lung Cancer: Control Rates from a Regional Cancer Centre I have no financial or personal relationships to disclose

  2. Technologies: - Four Dimensional CT Simulation - Integrated PET planning - Conformal Radiation Therapy - On board Cone Beam CT

  3. 45 pts

  4. NECC SABR - 48Gy in 4 fractions - VMAT Planning - SABR Tumor Board - Patient Selection • Medically inoperable • T1 or T2 <5cm • Biopsy proven or suspected NSCLCa

  5. NECC SABR Database Baseline demographics • T Stage • Size • Biopsy results • PET results • PFT • Dosimetry

  6. NECC SABR Database Follow up data – q3mos initially • Performance Status • Survival / Cause of death • Lesional control • Regional control • Distant control

  7. NECC SABR Database Follow up data – CTCAE 4.02 • Chest wall pain • Esophagitis • Pneumonitis • Pulmonary Hemorrhage

  8. Patients - 54 Patients were treated with 4800/12 - 26 Patients were treated with 5200/13 - 28 Patients were treated with 6000/15 - 76 Patients were treated with SABR of which 33 were peripheral lesions treated with 4800/4 Central lesions treated with 6000/8 were not analysed. Metastatic lesions are not included in this analysis.

  9. Hypofractionation Toxicity No Data collected

  10. SABR Toxicity Symptomatic Pneumonitis 0 Pulmonary Hemmorhage 0 Symptomatic Chest Wall Pain 1 Symptomatic Esophagitis 0 33 evaluable patients, Median follow up 245 Days

  11. NECC Hypofractionated Demographics

  12. Overall Survival (Hypofraction) (days)

  13. Lesional Control (Hypofraction) (days)

  14. Regional Disease (Hypofraction) (days)

  15. Metastatic Disease (Hypofraction) (days)

  16. Regional Disease (Hypofraction) (days)

  17. Metastatic Disease (Hypofraction) (days)

  18. Overall Survival (days)

  19. Lesional Control (days)

  20. Conclusion Radiotherapy for early stage lung cancer has advanced significantly at NECC. As of Feb 2015, over 76 SABR treatments have been delivered and 108 hypofractionated radiotherapy treatments. There is a non-significant trend towards improved lesional control with higher doses of RT with no change in regional control, development of metastatic disease, survival or toxicity.

More Related